{"ok":true,"entity":{"id":"regeneron-pharmaceuticals","name":"Regeneron","entityType":"company","officialName":"Regeneron Pharmaceuticals, Inc.","canonicalName":"Regeneron","displayName":"Regeneron","category":"バイオテクノロジー企業","shortDescription":"米国ニューヨーク州タリータウンに本社を置くバイオテクノロジー企業。VelocImmuneなど自社の遺伝子工学プラットフォームを用いた完全ヒト抗体創出を強みとする。眼科疾患のEylea、Sanofiと共同開発したDupixent、腫瘍領域のLibtayoを主要製品とする。","primaryCluster":"pharmaceuticals","parentEntity":null,"verificationStatus":"draft","website":"https://www.regeneron.com","updatedAt":"2026-08-06T01:18:46.240Z","secondaryClusters":[],"alias":[],"searchKeywords":["眼科疾患","免疫疾患","アレルギー","腫瘍","Eylea"]},"referenceIndex":["P-01-001","P-02-001","P-04-001","P-06-001","P-01-002"]}